2. Immunology/Inflammation
  3. Transmembrane Glycoprotein
  4. WM-A1-3389

WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN−γ, and TNF−α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer.

For research use only. We do not sell to patients.

WM-A1-3389

WM-A1-3389 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

WM-A1-3389 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN−γ, and TNF−α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer[1].

Species Reactivity

Human
In Vitro

WM-A1-3389 antibody (24 h) significantly increases secretion of Granzyme B, IFN−γ, and TNF−α in a co-culture system of human colon cancer HT29 cells and hPBMCs[1].
WM-A1-3389 antibody (24 h) significantly increases secretion of Granzyme B, IFN−γ, and TNF−α in a co-culture system of human biliary tract cancer Choi-CK cells and hPBMCs[1].
WM-A1-3389 antibody (24 h) significantly increases secretion of Granzyme B, IFN−γ, and TNF−α in a co-culture system of human head and neck cancer FaDu cells and hPBMCs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

WM-A1-3389 Related Antibodies
In Vivo

WM-A1-3389 antibody (30 mg/kg; i.p.; once every three days; four weeks) achieves 55.5 ± 4.4% tumor growth inhibition in humanized mice bearing HT29 colon cancer xenografts[1].
WM-A1-3389 antibody (3-30 mg/kg; i.p.; once every three days; two weeks) achieves dose-dependent tumor growth inhibition (50.8% to 68.7%) in C57BL/6N mice bearing MC38 colon cancer allografts[1].
WM-A1-3389 antibody (3-50 mg/kg; i.p.; once every three days; two weeks) achieves dose-dependent tumor growth inhibition (44.9% to 66.0%) in C57BL/6N mice bearing CT26 colon cancer allografts[1].
WM-A1-3389 antibody (30 mg/kg; i.p.; once every three days; three weeks) achieves 58.0 ± 4.3% tumor growth inhibition in humanized mice bearing Choi-CK biliary tract cancer xenografts[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: peripheral blood mononuclear cell humanized mice (6-week-old female; subcutaneous implantation of human colon cancer cell line HT29 cells)[1]
Dosage: 30 mg/kg
Administration: i.p.; once every three days; four weeks
Result: Achieved 55.5% tumor growth inhibition relative to the negative control group, with a statistically.
Animal Model: C57BL/6N mice (5-week-old female; subcutaneous implantation of mouse colon cancer cell line MC38 cells)[1]
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: i.p.; once every three days; two weeks
Result: Achieved 50.8% tumor growth inhibition relative to the negative control group at 3 mg/kg.
Achieved 58.2% tumor growth inhibition relative to the negative control group at 10 mg/kg.
Achieved 68.7% tumor growth inhibition relative to the negative control group at 30 mg/kg.
Showed a dose-dependent increase in tumor growth inhibition.
Animal Model: C57BL/6N mice (5-week-old female; subcutaneous implantation of mouse colon cancer cell line CT26 cells)[1]
Dosage: 3 mg/kg; 10 mg/kg; 50 mg/kg
Administration: i.p.; once every three days; two weeks
Result: Achieved 44.9% tumor growth inhibition relative to the negative control group at 3 mg/kg.
Achieved 57.0% tumor growth inhibition relative to the negative control group at 10 mg/kg.
Achieved 66.0% tumor growth inhibition relative to the negative control group at 50 mg/kg.
Showed a dose-dependent increase in tumor growth inhibition.
Animal Model: peripheral blood mononuclear cell humanized mice (6-week-old female; subcutaneous implantation of human biliary tract cancer cell line Choi-CK cells)[1]
Dosage: 30 mg/kg
Administration: i.p.; once every three days; three weeks
Result: Achieved 58.0% tumor growth inhibition relative to the negative control group, with a statistically.
Gene ID

3547  [NCBI]

Accession

Q8N6C5
Target

IGSF1
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[WM-A1-3389]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

WM-A1-3389 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

WM-A1-3389Transmembrane GlycoproteinHT29 cellsIGSF1Granzyme Bhead and neck cancerhPBMCsTNF-αcolon cancerbiliary tract cancerChoi-CK cellsIFN-γInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
WM-A1-3389
Cat. No.:
HY-P992021
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.